•Manual and saccadic measures of attention yield different developmental profiles.•Orienting measured by saccade-to-target showed no change between ages 6 to 12.•Orienting measured by manual button ...press task showed age-related change.•Manual target detection tasks measure skills above and beyond endogenous attention.•Endogenous visual attention is mature by age 6.
There is a long-standing assumption that covert measurement of orienting, the shifting of the “mind’s eye” independent of a saccade to a location in space, is a more “pure” measure of underlying attention than overt measurement of orienting. Testing attention covertly often relies on target detection tasks, which depend on making a decision about when and where a target has appeared and what is the appropriate action, all of which are potential confounds in measuring attention in children. This study cross-sectionally examined developmental profiles at ages 6–12 years of endogenous visual orienting. We used two tasks: one that measured orienting with a traditional covert attention button press response and one that measured orienting with eye tracking to measure overt saccades. The results obtained from the two orienting tasks demonstrate that each task measures distinct underlying processes with clear developmental profiles. Orienting, when measured by overt saccades, may be mature by 6 years of age, whereas the more complex manual response selection skills required in manual reaction time covert attention tasks continue to develop through middle childhood.
•Luminance levels of on-screen stimuli can affect colour discrimination in dogs.•Dogs can discriminate between coloured stimuli of equal physical isoluminance.•These findings have implications for ...studies of canine cognition using monitors.•Caution is advised when presenting coloured stimuli on screens.
Due to the composition of the cone photoreceptors in the retina of dogs, it has been proposed they might demonstrate human-like red/green colour blindness. However, some assessments have shown that dogs may still be able to distinguish between red and green. This suggests that dogs may be differentiating between the two colours on the basis of their brightness. To further explore this issue, the present investigation tested dogs’ abilities to differentiate between two colours at different physical luminance levels. Seven dogs were trained on a simultaneous size discrimination task in which two circles were presented on a monitor. The colours of the circles were then varied such that dogs would choose one stimulus if they could discriminate between two colours and a different stimulus if they could not. Four experiments were conducted. The first presented dogs with yellow, blue, green, and red stimuli at their maximum red, green, and blue (RGB) values. All seven dogs were equally proficient at discriminating between red and green, yellow and blue, and black and white stimuli as no difference in performance was observed (p = 0.52). In Experiments 2–4, the four colours were presented with equal physical luminance across three different intensities. All seven dogs successfully discriminated between all four colours when the colours were isoluminant at 34.6 cd/m2 as no differences in performance was observed (p = 0.10). When presented with isoluminant stimuli at 41.9 cd/m2, a difference was observed between conditions, with the dogs failing to detect red stimuli presented on a green background compared to the achromatic controls (p = 0.03). When presented with stimuli at 49.3 cd/m2, a difference was again observed between conditions, but this time the dogs were unable to detect blue stimuli presented on a yellow background compared to the achromatic controls (p < 0.01). These findings demonstrate that luminance levels of stimuli can affect colour discrimination and what dogs are able to see on computer screens. These results have important implications in how cognition is studied in dogs through the use of presenting stimuli on monitors.
Hydrogen selenide (H
Se) is a central metabolite in the biological processing of selenium for incorporation into selenoproteins, which play crucial antioxidant roles in biological systems. Despite ...being integral to proper physiological function, this reactive selenium species (RSeS) has received limited attention. We recently reported an early example of a H
Se donor (TDN1042) that exhibited slow, sustained release through hydrolysis. Here we expand that technology based on the P═Se motif to develop cyclic-PSe compounds with increased rates of hydrolysis and function through well-defined mechanisms as monitored by
P and
Se NMR spectroscopy. In addition, we report a colorimetric method based on the reaction of H
Se with NBD-Cl to generate NBD-SeH (λ
= 551 nm), which can be used to detect free H
Se. Furthermore, we use TOF-SIMS (time of flight secondary ion mass spectroscopy) to demonstrate that these H
Se donors are cell permeable and use this technique for spatial mapping of the intracellular Se content after H
Se delivery. Moreover, these H
Se donors reduce endogenous intracellular reactive oxygen species (ROS) levels. Taken together, this work expands the toolbox of H
Se donor technology and sets the stage for future work focused on the biological activity and beneficial applications of H
Se and related bioinorganic RSeS.
•Little is known about how to engage patients and families in collaborative care programs for depression and anxiety disorders.•Our systematic review identifies 27 strategies for patient and family ...engagement in collaborative care.•The engagement of patients and families was limited in most programs.•Personalized care planning, shared decision making, and family or peer supports were adopted in fewer than one third of programs.•Patients and families were rarely involved in the design or evaluation of collaborative care programs.
Patients and families are often referred to as important partners in collaborative mental health care (CMHC). However, how to meaningfully engage them as partners remains unclear. We aimed to identify strategies for engaging patients and families in CMHC programs for depression and anxiety disorders.
We updated a Cochrane review of CMHC programs for depression and anxiety disorders. Searches were conducted in Cochrane CCDAN and CINAHL, complemented by additional database searches, trial registry searches, and cluster searches for ‘sibling’ articles. Coding and data extraction of engagement strategies was an iterative process guided by a conceptual framework. We used narrative synthesis and descriptive statistics to report on findings.
We found 148 unique CMCH programs, described in 578 articles. Most programs (96%) featured at least one strategy for engaging patients or families. Programs adopted 15 different strategies overall, with a median of two strategies per program (range 0–9 strategies). The most common strategies were patient education (87% of programs) and self-management supports (47% of programs). Personalized care planning, shared decision making, and family or peer supports were identified in fewer than one third of programs.
Our search strategy was designed to capture programs evaluated in clinical trials and so other innovative programs not studied in trials were likely missed.
Most CMHC programs for depression and anxiety disorders adopted a limited number of strategies to engage patients and families in their care. However, this review identifies numerous strategies that can be used to strengthen the patient- and family-centeredness of collaborative care.
Susceptibility to geometrical visual illusions has been tested in a number of non-human animal species, providing important information about how these species perceive their environment. Considering ...their active role in human lives, visual illusion susceptibility was tested in domestic dogs (
Canis familiaris
). Using a two-choice simultaneous discrimination paradigm, eight dogs were trained to indicate which of two presented circles appeared largest. These circles were then embedded in three different illusory displays; a classical display of the Ebbinghaus–Titchener illusion; an illusory contour version of the Ebbinghaus–Titchener illusion; and the classical display of the Delboeuf illusion. Significant results were observed in both the classical and illusory contour versions of the Ebbinghaus–Titchener illusion, but not the Delboeuf illusion. However, this susceptibility was reversed from what is typically seen in humans and most mammals. Dogs consistently indicated that the target circle typically appearing larger in humans appeared smaller to them, and that the target circle typically appearing smaller in humans, appeared larger to them. We speculate that these results are best explained by assimilation theory rather than other visual cognitive theories explaining susceptibility to this illusion in humans. In this context, we argue that our findings appear to reflect higher-order conceptual processing in dogs that cannot be explained by accounts restricted to low-level mechanisms of early visual processing.
•A two-choice discrimination task assessed relational class concept learning in dogs.•Dogs exhibited conceptual behaviour in the form of relational concept learning.•There were differences in dog’s ...generalization capabilities across certain shapes.•Behavioral stimulus generalization does not explain performance.
One central issue in the study of animal cognition concerns conceptual behaviour, where an organism categorises objects, events, and relationships so as to transfer previously learned rules to novel contexts. In this study, we investigated whether or not dogs demonstrate conceptual behaviour in the form of simple relational class concept learning. A two-choice visual discrimination task was used to assess if dogs are capable of simple relational class concept learning by generalising the same rule (i.e. circle is larger or smaller than) to various novel shapes. Eight purebred Lagotto Romagnolos were included in the study. The results demonstrated that they were capable of generalising a previously learned size discrimination rule to novel stimuli; however, there were differences in dog’s generalization capabilities across certain shapes. Considering their unique relationship with humans, and their immediacy in everyday life, a better understanding of conceptual behaviour and generalising abilities in domestic dogs may have implications for training and management methods, as well as contributing to comparative psychology and applied ethology.
To assess the clinical manifestations and predictors of different types of tremors in individuals with different types of isolated dystonia.
Clinical manifestations of tremor were assessed in a ...multicenter, international cross-sectional, cohort study of 2,362 individuals with all types of isolated dystonia (focal, segmental, multifocal, and generalized) recruited through the Dystonia Coalition.
Methodical and standardized assessments of all participants in this cohort revealed the overall prevalence of any type of tremor was 53.3%. The prevalence of dystonic tremor varied from 36.9% to 48.4%, depending on criteria used to define it. To identify the factors associated with tremors in dystonia, the data were analyzed by generalized linear modeling and cluster analyses. Generalized linear modeling indicated 2 of the strongest factors associated with tremor included body region affected by dystonia and recruitment center. Tremor was also associated with severity of dystonia and duration of dystonia, but not with sex or race. The cluster analysis distinguished 8 subgroups within the whole cohort; defined largely by body region with dystonia, and secondarily by other clinical characteristics.
The large number of cases evaluated by an international team of movement disorder experts facilitated the dissection of several important factors that influence the apparent prevalence and phenomenology of tremor in dystonia. These results are valuable for understanding the many differences reported in prior studies, and for guiding future studies of the nosology of tremor and dystonia.
Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposure while ...preserving key pharmacological activity.
To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease.
Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea score of 8 or higher (range, 0-28; lower score indicates less chorea) were enrolled from August 2013 to August 2014 and randomized to receive deutetrabenazine (n = 45) or placebo (n = 45) in a double-blind fashion at 34 Huntington Study Group sites.
Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 weeks, followed by a 1-week washout.
Primary end point was the total maximal chorea score change from baseline (the average of values from the screening and day-0 visits) to maintenance therapy (the average of values from the week 9 and 12 visits) obtained by in-person visits. This study was designed to detect a 2.7-unit treatment difference in scores. The secondary end points, assessed hierarchically, were the proportion of patients who achieved treatment success on the Patient Global Impression of Change (PGIC) and on the Clinical Global Impression of Change (CGIC), the change in 36-Item Short Form- physical functioning subscale score (SF-36), and the change in the Berg Balance Test.
Ninety patients with Huntington disease (mean age, 53.7 years; 40 women 44.4%) were enrolled. In the deutetrabenazine group, the mean total maximal chorea scores improved from 12.1 (95% CI, 11.2-12.9) to 7.7 (95% CI, 6.5-8.9), whereas in the placebo group, scores improved from 13.2 (95% CI, 12.2-14.3) to 11.3 (95% CI, 10.0-12.5); the mean between-group difference was -2.5 units (95% CI, -3.7 to -1.3) (P < .001). Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002). As measured by the CGIC, treatment success occurred in 19 patients (42%) in the deutetrabenazine group vs 6 (13%) in the placebo group (P = .002). In the deutetrabenazine group, the mean SF-36 physical functioning subscale scores decreased from 47.5 (95% CI, 44.3-50.8) to 47.4 (44.3-50.5), whereas in the placebo group, scores decreased from 43.2 (95% CI, 40.2-46.3) to 39.9 (95% CI, 36.2-43.6), for a treatment benefit of 4.3 (95% CI, 0.4 to 8.3) (P = .03). There was no difference between groups (mean difference of 1.0 unit; 95% CI, -0.3 to 2.3; P = .14), for improvement in the Berg Balance Test, which improved by 2.2 units (95% CI, 1.3-3.1) in the deutetrabenazine group and by 1.3 units (95% CI, 0.4-2.2) in the placebo group. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia.
Among patients with chorea associated with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 weeks. Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety.
clinicaltrials.gov Identifier: NCT01795859.
PDF
